M&A / Jazz’s $7.2 Billion GW Pharma Deal: A Major Boost for Cannabinoid Research
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
Address: St John’s Innovation Centre Cowley Road Cambridge CB4 0WS ,United Kingdom
Tel: + 44 (0) 1223 421411
Web: http://tiger.directrouter.co.uk/cgi-sys/defaultwebpage.cgi
Altacor is an Ophthalmic Specialty Pharmaceutical Company specialising in marketing and development of differentiated products which have been designed for the needs of both ophthalmologists and patients.
From its headquarters in Cambridge UK, Altacor is using its drug development skills and in depth market knowledge to build a portfolio of high quality, differentiated prescription medicines that set new standards in the sector. The company has a sales infrastructure which is active in the secondary care sector and in accessing primary care and promoting the prescription products Clinitas and Clinitas Gel. Altacor is also working in the pharmacy and optical channels through which its OTC products – the Clinitas range for all dry eye conditions, are being promoted.
Altacor’s pipeline consists of development products for Ocular Surface Disease, Ocular Infection and Glaucoma. The company’s products are differentiated by formulation or reprofiling, patented active or delivery systems and presented in multidose or preservative-free single use containers.
Altacor has strong skills in drug formulation, reprofiling and development through its extensive network and understanding of the European regulatory environment which results in a uniquely focused company.
Altacor has three areas of therapeutic interest
1. Ocular Surface Disease including Dry Eye syndrome
2. Ocular Infection
3. Glaucoma
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to…
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed…
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central…
Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical…
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British…
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are…
With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is…
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British…
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019…
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019,…
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial…